文献速递慢阻肺

COPD患者FEV1加速下降与心血管疾病及死亡风险

Accelerated FEV1 decline and risk of cardiovascular disease and mortality in a primary care population of COPD patients.
PubMed 文献 · Eur Respir J · 2021-03-04

加速FEV1下降与复合心血管结局及死亡风险无显著关联(HRadj 0.98,95%CI 0.90-1.06),而心血管风险与mMRC评分≤2及前一年≥2次急性加重相关。

要点

  • 加速FEV1下降未增加COPD患者心血管事件及死亡风险。
  • 心血管风险与mMRC评分≤2及前一年≥2次急性加重相关。
  • 需关注急性加重频率和呼吸困难程度以评估心血管风险。

核心结论

  • 在初级保健COPD人群中,加速FEV1下降与心血管疾病结局及死亡风险无显著关联。
  • 心血管结局和死亡与急性加重频率、严重程度及mMRC呼吸困难评分升高相关。

研究设计与样本

  • 加速FEV1下降定义为COPD人群FEV1下降最快四分位(> -40.5 mL·年-1)。
  • 采用Cox回归评估基线加速FEV1下降与复合心血管结局的关联,随访中位3.6年(IQR 1.7-6.1年)。

主要发现

  • 随访期间6110例(16.8%)发生心血管事件。
  • 加速与非加速FEV1下降患者的心血管疾病及死亡风险相似(HRadj 0.98,95%CI 0.90-1.06)。
  • 心力衰竭HR 0.99(95%CI 0.83-1.20),心肌梗死HR 0.89(95%CI 0.70-1.12),卒中HR 1.01(95%CI 0.82-1.23),心房颤动HR 0.97(95%CI 0.81-1.15),冠状动脉疾病HR 1.02(95%CI 0.87-1.19),心血管死亡HR 0.94(95%CI 0.71-1.25)。
  • 心血管风险与mMRC评分≤2及前一年≥2次急性加重相关。

临床怎么用

  • 在初级保健COPD患者中,不应仅依据FEV1下降速度评估心血管风险。
  • 应关注急性加重频率和mMRC呼吸困难评分以识别心血管高风险患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Accelerated lung function decline has been associated with increased risk of cardiovascular disease (CVD) in a general population, but little is known about this association in chronic obstructive pulmonary disease (COPD). We investigated the association between accelerated lung function decline and CVD outcomes and mortality in a primary care COPD population.COPD patients without a history of CVD were identified in the Clinical Practice Research Datalink (CPRD)-GOLD primary care dataset (n=36 382). Accelerated decline in forced expiratory volume in 1 s (FEV1) was defined using the fastest quartile of the COPD population's decline. A Cox regression was used to assess the association between baseline accelerated FEV1 decline and a composite CVD outcome over follow-up (myocardial infarction, ischaemic stroke, heart failure, atrial fibrillation, coronary artery disease and CVD mortality). The model was adjusted for age, sex, smoking status, body mass index, history of asthma, hypertension, diabetes, statin use, Modified Medical Research Council (mMRC) dyspnoea score, exacerbation frequency and baseline FEV1 % predicted.6110 COPD patients (16.8%) had a CVD event during follow-up; median length of follow-up was 3.6 years (interquartile range (IQR) 1.7-6.1 years). Median rate of FEV1 decline was -19.4 mL·year-1 (IQR -40.5-1.9); 9095 patients (25%) had accelerated FEV1 decline (> -40.5 mL·year-1), 27 287 (75%) did not (≤ -40.5 mL·year-1). Risk of CVD and mortality was similar between patients with and without accelerated FEV1 decline (HRadj 0.98, 95% CI 0.90-1.06). Corresponding risk estimates were 0.99 (95% CI 0.83-1.20) for heart failure, 0.89 (95% CI 0.70-1.12) for myocardial infarction, 1.01 (95% CI 0.82-1.23) for stroke, 0.97 (95% CI 0.81-1.15) for atrial fibrillation, 1.02 (95% CI 0.87-1.19) for coronary artery disease and 0.94 (95% CI 0.71-1.25) for CVD mortality. Rather, risk of CVD was associated with a mMRC score ≤2 and two or more exacerbations in the year prior.CVD outcomes and mortality were associated with exacerbation frequency and severity and increased mMRC dyspnoea score but not with accelerated FEV1 decline.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Whittaker HR, Bloom C, Morgan A, et al. Accelerated FEV1 decline and risk of cardiovascular disease and mortality in a primary care population of COPD patients. Eur Respir J. 2021. PMID: 32972984. doi:10.1183/13993003.00918-2020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。